Finanzen von Radiopharm Theranostics Ltd (RADX)RADXRadiopharm Theranostics Ltd

Evaluating the bottom line, Radiopharm Theranostics Ltd maintains a gross margin of -90.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2245.03%, while the net margin is -1946.20%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RADX converts its operational activities into shareholder value.

In the context of the broader market, RADX competes directly with industry leaders such as DCGO and MBAI. With a market capitalization of $16.39M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of -90.30% stands against DCGO's 26.85% and MBAI's N/A. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.

Radiopharm has a forward P/E of 0, indicating no earnings forecasted, and a price-to-sales ratio of 1.09, suggesting the stock is relatively cheap compared to its sales. However, the negative cash flow metrics raise concerns about its financial health.